Eric Jonasch
Overview
Explore the profile of Eric Jonasch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
248
Citations
10391
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wiley H, Srinivasan R, Maranchie J, Chhablani J, Bondergaard Iversen A, Kruse A, et al.
Ophthalmology
. 2025 Feb;
132(3):374.
PMID: 39986707
No abstract available.
2.
Moussa M, Khandelwal J, Wilson N, Malikayil K, Surasi D, Bathala T, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39939142
Background: Nivolumab plus ipilimumab (nivo/ipi) is a standard of care first-line (1 L) therapy for patients with metastatic clear-cell renal cell carcinoma (ccRCC), but its role in patients with metastatic,...
3.
Bex A, Jewett M, Lewis B, Abel E, Albiges L, Berg S, et al.
Eur Urol
. 2025 Jan;
PMID: 39855942
Neoadjuvant systemic treatment strategies have improved outcomes in several solid tumour types. This success has not yet been replicated in renal cell carcinoma (RCC). A consensus and international collaboration are...
4.
Berg S, La Rosa S, Zhang T, Pierorazio P, Albiges L, Beckermann K, et al.
Urol Oncol
. 2024 Nov;
43(3):135-146.
PMID: 39500687
Modern advances in systemic and localized therapies for patients with renal cell carcinoma (RCC) have significantly improved patients' outcomes. If disease progression occurs after initial treatment, clinicians often have multiple...
5.
Wang E, Rupe E, Mukhida S, Johns A, Campbell M, Shah A, et al.
Eur Urol Focus
. 2024 Sep;
PMID: 39307587
Background And Objective: Belzutifan, a hypoxia-inducible factor 2 alpha inhibitor, was approved initially for patients with von Hippel-Lindau disease and more recently for sporadic, metastatic clear cell renal cell carcinoma...
6.
Iliopoulos O, Iversen A, Narayan V, Maughan B, Beckermann K, Oudard S, et al.
Lancet Oncol
. 2024 Sep;
25(10):1325-1336.
PMID: 39284337
Background: The first-in-class hypoxia-inducible factor-2α inhibitor, belzutifan, showed clinically meaningful antitumour activity in von Hippel-Lindau (VHL) disease-associated neoplasms in the ongoing, single-arm, phase 2 LITESPARK-004 study. We aimed to investigate...
7.
Wiley H, Srinivasan R, Maranchie J, Chhablani J, Bondergaard Iversen A, Kruse A, et al.
Ophthalmology
. 2024 Jun;
131(11):1324-1332.
PMID: 38849055
Purpose: To report the efficacy of the oral hypoxia-inducible factor 2α inhibitor belzutifan in participants with von Hippel-Lindau disease-associated retinal hemangioblastomas in the LITESPARK-004 study. Design: Subgroup analysis of the...
8.
Wolf M, Madden M, Arner E, Bader J, Ye X, Vlach L, et al.
J Clin Invest
. 2024 Apr;
134(8.
PMID: 38618956
Clear cell renal cell carcinoma (ccRCC) is characterized by dysregulated hypoxia signaling and a tumor microenvironment (TME) highly enriched in myeloid and lymphoid cells. Loss of the von Hippel Lindau...
9.
Motzer R, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, et al.
J Natl Compr Canc Netw
. 2024 Feb;
22(1):4-16.
PMID: 38394781
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on the systemic...
10.
Else T, Jonasch E, Iliopoulos O, Beckermann K, Narayan V, Maughan B, et al.
Clin Cancer Res
. 2024 Feb;
30(9):1750-1757.
PMID: 38393723
Purpose: Primary analysis of the ongoing, single-arm, phase 2 LITESPARK-004 study (NCT03401788) showed clinically meaningful antitumor activity in von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC) and other neoplasms with...